Hepatopancreatobiliary Carcinoma — Trials

Hepatopancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,361
Recruiting: 790
Ph III recruiting: 74
Growth YoY: +9.6%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (646)

clinicaltrialsPublishedShowing 351–400 of 5,154 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05211323	A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer	active not recruiting	Phase 2	4	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials
NCT05701488	SIRT With Tremelimumab and Durvalumab for Resectable HCC	active not recruiting	Phase 1	20	Jiping Wang, MD, PhDOTHER	1	Aug 13, 2026	clinicaltrials